Therapeutic Potential of Oxiracetam in Neurocognitive Disorders: A Narrative Review
Hafsa Ali, Syeda Maliha, Sundas Ishtiaq, Omer Al‐Karawi, Mohammed Hammad Jaber Amin · 2026
Read Therapeutic Potential of Oxiracetam in Neurocognitive Disorders: A Narrative Review by Hafsa Ali, Syeda Maliha, Sundas Ishtiaq, Omer Al‐Karawi, Mohammed Hammad Jaber Amin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13527391.txt.
Description
Hafsa Ali and co-authors review, in a 2026 paper, the promise of oxiracetam, a brain drug of the racetam family, for disorders of memory and thinking. Standard drugs for cognitive decline help only modestly and unevenly. Oxiracetam has been studied for decades across brain injury, stroke, and dementia, and the authors gather the mechanistic and clinical evidence in one narrative account.
Lab work credits the drug with several actions: boosting a key memory chemical system, tuning AMPA receptors, aiding the strengthening of connections between neurons, and damping oxidation and inflammation. Trial results in patients are mixed, with some studies showing clear gains and others none over placebo. The safety record looks kind. The authors call the drug promising but unproven, and they ask for large, careful multicenter trials.
Catalog record
| CREATOR | Hafsa Ali, Syeda Maliha, Sundas Ishtiaq, Omer Al‐Karawi, Mohammed Hammad Jaber Amin |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |